Lv2
115 积分 2020-08-03 加入
Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib
9小时前
待确认
Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy
9小时前
已完结
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
9小时前
已完结
Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer
10小时前
已完结
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3
10小时前
已完结
Personalized Care for Patients With EGFR-mutant Nonsmall Cell Lung Cancer: Navigating Early to Advanced Disease Management
10小时前
已完结
Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors
10小时前
已完结
Meta-Analysis of the Prognostic Impact of TP53 Co-Mutations in EGFR-mutant Advanced Non-Small-Cell Lung Cancer Treated With Tyrosine Kinase Inhibitors. Crit Rev Oncol Hematol
10小时前
求助中
皖公网安备34019202002308
